Trials / Completed
CompletedNCT00465959
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
Safety, Tolerability, Pharmacokinetics, and Efficacy of Single Inhaled Administrations of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- —
Summary
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trospium chloride inhalation powder (TrIP) | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2007-04-27
- Last updated
- 2013-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00465959. Inclusion in this directory is not an endorsement.